US 11,998,561 B2
Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders
Eric Alexander Marcotulli, New York, NY (US); and Daniel Antonio Alminana, New York, NY (US)
Assigned to Elysium Health, Inc., New York, NY (US)
Filed by Elysium Health, Inc., New York, NY (US)
Filed on Jan. 21, 2022, as Appl. No. 17/580,999.
Application 17/580,999 is a continuation of application No. 16/327,651, granted, now 11,260,069, previously published as PCT/US2017/047979, filed on Aug. 22, 2017.
Claims priority of provisional application 62/378,053, filed on Aug. 22, 2016.
Prior Publication US 2022/0143055 A1, May 12, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/706 (2006.01); A61K 31/09 (2006.01); A61P 25/16 (2006.01); A61P 25/28 (2006.01)
CPC A61K 31/706 (2013.01) [A61K 31/09 (2013.01); A61P 25/16 (2018.01); A61P 25/28 (2018.01)] 19 Claims
 
1. A method of reducing the prevalence of indicia of a neurodegenerative disease in a subject in need thereof comprising administering to the subject a composition consisting of nicotinamide riboside, pterostilbene and a pharmaceutically acceptable carrier and/or excipient, wherein the composition is administered to the subject daily, and the daily dose of nicotinamide riboside is at least 100 mg and the daily dose of pterostilbene is at least 25 mg.